Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Myelodysplastic Syndrome

Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with IPSS risk category of low-risk or Intermediate-1 MDS. This study will be conducted in two phases. In phase 1 subjects will be randomized into 3 cohorts in a 28-day cycles. Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses / schedules.
Myelodysplastic Syndrome
I/II
Mohan, Sanjay
NCT03502668
VICCHEM1967

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: